Provectus Biopharmaceuticals’ PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference

Sheraton New York Times Square, Friday, April 11, 2014

Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on PV-10 for cutaneous melanoma will be included in a session at HemOnc Today – Melanoma and Cutaneous Malignancies Conference. HemOnc Today will be held this year at the Sheraton New York Times Square in New York City on Friday, April 11 and Saturday, April 12, 2014.

Dr. Robert H.I. Andtbacka, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, will moderate Session 4: Local and Regional Therapy. Session 4 will be held on Friday, April 11 at 2:15 pm. Sanjiv S. Agarwala, MD, Program Director of the Conference, has said data regarding “PV-10 will be an integral part of session 4.” Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study.

Craig Dees, PhD, CEO of Provectus said, "We are very pleased to have our data form such a significant part of this important, cutting-edge conference.”

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, 866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon Nurse, 212-564-4700DM, SVP – Investor RelationsorBill Gordon, 212-724-6312Media Relations

Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024